1-5 of 5
Sue Naim
Close
Sort by
Journal Articles

Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Guillermo Garcia-Manero, MD, Ellen K. Ritchie, MD, Katherine J. Walsh, MD, Michael R. Savona, MD, Hagop M. Kantarjian, MD, Patricia L. Kropf, MD, Casey L. O'Connell, MD, Raoul Tibes, MD PhD, Naval G. Daver, MD, Elias J. Jabbour, MD, Scott D. Lunin, MD, Todd L. Rosenblat, MD MS, Karen W.L. Yee, MD, Wendy Stock, MD, Elizabeth A. Griffiths, MD, Joseph Mace, MD, Nikolai A. Podoltsev, MD PhD, Jesus G. Berdeja, MD, Jean-Pierre Issa, MD, Sue Naim, Yong Hao, MD, Mohammad Azab, MD, Gail J. Roboz, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 231.
https://doi.org/10.1182/blood-2018-99-110465
Published: 2018
Journal Articles

Genetic Determinants of Response to Guadecitabine (SGI-110) in AML

Patricia L. Kropf, MD, Woonbok Chung, PhD, Andrew D. Kelly, BA, Hagop M. Kantarjian, MD, Gail J. Roboz, Karen W.L. Yee, MD, Pietro Taverna, PhD, Sue Naim, Mohammad Azab, MD, Jaroslav Jelinek, MD PhD, Jean-Pierre J. Issa, MD
Journal: Blood
Blood (2016) 128 (22): 1680.
https://doi.org/10.1182/blood.V128.22.1680.1680
Published: 2016
Journal Articles

First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Guillermo Garcia-Manero, MD, Ellen K. Ritchie, MD, Katherine Walsh, MD, Michael Savona, MD, Patricia Kropf, MD, Casey O'Connell, MD, Raoul Tibes, MD, Naval G. Daver, MD, Elias Jabbour, MD, Scott Lunin, MD, Todd L. Rosenblat, MD, Karen Yee, MD, Wendy Stock, MD, Elizabeth A. Griffiths, MD, Joseph R Mace, MD, Nikolai A. Podoltsev, MDPhD, Jesus G. Berdeja, MD, Jean-Pierre Issa, MD, Woonbok Chung, PhD, Sue Naim, Pietro Taverna, PhD, Yong Hao, PhD, Mohammad Azab, MD, Hagop M. Kantarjian, MD, Gail J. Roboz, MD
Journal: Blood
Blood (2014) 124 (21): 529.
https://doi.org/10.1182/blood.V124.21.529.529
Published: 2014
Journal Articles

DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML

Gail J. Roboz, MD, Jean-Pierre Issa, MD, David Rizzieri, MD, Wendy Stock, MD, Casey O'Connell, MD, Karen Yee, MD, Raoul Tibes, MD, Elizabeth A. Griffiths, MD, Katherine Walsh, MD, Eric J. Feldman, MD, Ellen Ritchie, MD, Arati V. Rao, MD, Richard A. Larson, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Elias Jabbour, MD, Jorge E. Cortes, MD, Aaron Schimmer, PhD, MD, Ruben A. Mesa, MD, William Blum, MD, Woonbok Chung, PhD, Sue Naim, Pietro Taverna, PhD, Yong Hao, PhD, Gavin Choy, PharmD, Mohammad Azab, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2013) 122 (21): 1548.
https://doi.org/10.1182/blood.V122.21.1548.1548
Published: 2013
Journal Articles

First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML)

Hagop M. Kantarjian, MD, Elias Jabbour, MD, Karen Yee, MD, Patricia Kropf, MD, Casey O'Connell, MD, Wendy Stock, MD, Raoul Tibes, MD, PhD, David Rizzieri, MD, Katherine Walsh, MD, Elizabeth A. Griffiths, MD, Gail J. Roboz, MD, Michael Savona, MD, Thomas Ervin, MD, Nikolai A. Podoltsev, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, William G. Wierda, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Joseph M. Brandwein, MD, Olatoyosi Odenike, MBBS, Eric J. Feldman, MD, Woonbok Chung, PhD, Sue Naim, Gavin Choy, PharmD, Pietro Taverna, PhD, Yong Hao, PhD, George Dimitrov, MD, Mohammad Azab, MD, Jean-Pierre Issa, MD
Journal: Blood
Blood (2013) 122 (21): 497.
https://doi.org/10.1182/blood.V122.21.497.497
Published: 2013